{"id":"W2995427723","doi":"10.1007/s12325-019-01169-0","title":"Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia","year":2019,"lang":"en","type":"letter","venue":"Advances in Therapy","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"EVRAZ (Canada); TransCanada (Canada)","funders":"Pfizer","keywords":"Blinatumomab; Medicine; Refractory (planetary science); Lymphoblastic Leukemia; Internal medicine; Oncology; Salvage therapy; Pediatrics; Leukemia; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003094681,0.0006609241,0.001802935,0.0007729137,0.002012444,0.002384098,0.001694032,0.02449407,0.008324848],"category_scores_gemma":[0.02479768,0.0005113785,0.001131634,0.0008820296,0.0009453943,0.001617266,0.0006766572,0.01787479,0.006927394],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003748135,"about_ca_system_score_gemma":0.003430231,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00314333,"about_ca_topic_score_gemma":0.004607512,"domain_scores_codex":[0.9977198,0.000874919,0.0003777735,0.000271731,0.0004856579,0.0002701759],"domain_scores_gemma":[0.9918336,0.004155886,0.0007842237,0.0002203519,0.002025127,0.0009807509],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001920353,0.00003867686,0.0004336651,0.00006718143,0.0000181733,0.001110725,0.00003054064,0.00004398212,0.00008489532,0.000392848,0.9934788,0.00410843],"study_design_scores_gemma":[0.0008399415,0.0003476181,0.003290477,0.000636012,0.0001591883,0.004360332,0.0004025712,0.0009051479,0.000744352,0.004719119,0.9834781,0.0001171235],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0006885424,0.001067976,0.00008398056,0.944419,0.05151158,0.00003345955,0.0002566423,0.00005671938,0.001882149],"genre_scores_gemma":[0.005374856,0.0009462769,0.0002350842,0.9262339,0.06164882,0.00007817669,0.0001061059,0.00004063586,0.00533618],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.02449407,"threshold_uncertainty_score":0.02784944,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03605871875456865,"score_gpt":0.3624977746121067,"score_spread":0.3264390558575381,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}